Practice Management News

The most efficacious targeted therapies for VEXAS syndrome are Janus kinase inhibitors and interleukin-6 inhibitors, while IL-1 and TNF blockers are less effective, according to data published in the Annals of the Rheumatic Diseases.

In this episode, we dive into the story of aspirin and the development of ibuprofen, ending with the experiments that showed the mechanism of how aspirin actually works.

Treatment with the novel antibody CM313 boosted platelet levels and demonstrated long-term durability among adults with immune thrombocytopenia, results from a phase 2 study showed.

In this video exclusive, Leonard Calabrese, DO, chief medical editor of Healio Rheumatology, highlights what he describes as “an outstanding roundtable” in the June issue on advanced practice providers’ expanding role in rheumatology care.

This month’s featured roundtable on the evolving and broadening role of advanced practice providers in rheumatologic care is a timely discussion, and I give a big thanks to Carrie Beach, BSN, RN-BC; Jeffrey Curtis, MD, MS, MPH; Amanda Mixon, PA-C; Kenneth G. Saag, MD; and Christine Stamatos, DNP, ANP-C.

The number, and role, of advanced practice providers in rheumatology care is exploding.

The concept of delayed gratification has been ingrained in us throughout medical school and residency. This mentality can sometimes lead to explosive spending as an attending when one enjoys a significant salary boost.

Skin manifestations are common in VEXAS syndrome and evaluating their presentations can assist in genotyping the disease and possibly lead to better diagnoses, according to a study.

The Council for Medical Specialty Societies, or CMSS, announced the launch of a new initiative that aims to reduce clinicians’ reliance on race in clinical decision-making and patient harms.

A possible genetic rationale for why women acquire more autoimmune diseases than men has been discovered, according to findings published recently in Cell.